Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
SLC6A4 6532 FENFLURAMINE CHEMBL87493 inhibitor DrugBank 16452989, 14675103, 18991872, 14515341, 20610163
SLC6A4 6532 VERAPAMIL CHEMBL6966 DrugBank 9537821, 2940099
SLC6A4 6532 COCAINE CHEMBL370805 inhibitor TdgClinicalTrial, TEND, DrugBank 8302852, 15351386, 10366604, 9537821, 12057823
SLC6A4 6532 SIBUTRAMINE CHEMBL1419 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 18671470, 17284621, 10929704, 19475780, 17544870, 11152984, 12417543, 15685250, 15944869, 15382615, 16678551
SLC6A4 6532 CHLORPHENIRAMINE POLISTIREX CHEMBL1201659 inhibitor DrugBank 9537821
SLC6A4 6532 METHYLENEDIOXYMETHAMPHETAMINE CHEMBL43048 negative modulator DrugBank 11994534, 12742084, 12398910, 14700733, 10607865, 11756522
SLC6A4 6532 CHEMBL294144 CHEMBL294144 TdgClinicalTrial, DrugBank
SLC6A4 6532 VORTIOXETINE CHEMBL2104993 inhibitor, Inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 21486038
SLC6A4 6532 AMITRIPTYLINE CHEMBL629 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 DAPOXETINE CHEMBL2110900 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions
SLC6A4 6532 NEFAZODONE CHEMBL623 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 PAROXETINE CHEMBL490 inhibitor PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 [3H]PAROXETINE CHEMBL1628650 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 TRIMIPRAMINE CHEMBL644 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 EVODIAMINE CHEMBL486598 PharmGKB
SLC6A4 6532 LOXAPINE CHEMBL831 binder DrugBank
SLC6A4 6532 AMOXAPINE CHEMBL1113 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 9537821, 7984281
SLC6A4 6532 MAZINDOL CHEMBL781 inhibitor DrugBank 9537821
SLC6A4 6532 MINAPRINE CHEMBL278819 inhibitor TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
SLC6A4 6532 AMINEPTINE CHEMBL418995 DrugBank 17139284, 17016423
SLC6A4 6532 MIANSERIN CHEMBL6437 inhibitor DrugBank 9537821
SLC6A4 6532 METHYL SALICYLATE CHEMBL108545 inhibitor DrugBank
SLC6A4 6532 ATOMOXETINE CHEMBL641 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 DESVENLAFAXINE CHEMBL1118 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 DULOXETINE CHEMBL1175 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 LOFEPRAMINE CHEMBL87708 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 MILNACIPRAN CHEMBL259209 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 NORTRIPTYLINE CHEMBL445 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 PHENELZINE CHEMBL1089 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 [3H]CITALOPRAM CHEMBL1628605 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 ZOTEPINE CHEMBL285802 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 PHENTERMINE CHEMBL1574 TdgClinicalTrial, TEND
SLC6A4 6532 ONDANSETRON CHEMBL46 PharmGKB
SLC6A4 6532 RISPERIDONE CHEMBL85 PharmGKB
SLC6A4 6532 CHEMBL488638 CHEMBL488638 TdgClinicalTrial
SLC6A4 6532 ITI-007 (CHEMBL3545044) CHEMBL3545044 TdgClinicalTrial
SLC6A4 6532 AMPHETAMINE CHEMBL405 binder DrugBank 17209801
SLC6A4 6532 PARA-METHOXYAMPHETAMINE CHEMBL278663 inhibitor DrugBank 11994534, 11041537, 12742084, 12398910, 14700733, 10607865, 11756522
SLC6A4 6532 METHAMPHETAMINE CHEMBL1201201 negative modulator TdgClinicalTrial, DrugBank 20226815, 19607959, 17673199
SLC6A4 6532 ZIMELDINE CHEMBL37744 DrugBank 9537821, 17139284, 17016423
SLC6A4 6532 CLOMIPRAMINE CHEMBL415 inhibitor PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 DESIPRAMINE CHEMBL72 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 ESCITALOPRAM CHEMBL1508 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 IMIPRAMINE CHEMBL11 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 SERTRALINE CHEMBL809 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 VENLAFAXINE CHEMBL637 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 ZIPRASIDONE CHEMBL708 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 BERBERINE CHEMBL295124 PharmGKB
SLC6A4 6532 METHYLPHENIDATE CHEMBL796 TdgClinicalTrial, TEND
SLC6A4 6532 MIRTAZAPINE CHEMBL654 binder DrugBank 15771415, 9537821
SLC6A4 6532 FLUOXETINE CHEMBL41 inhibitor PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, NCI, TEND, DrugBank 17289086, 17215106, 17335951, 11752352, 9537821, 17356573, 17486443, 11487610
SLC6A4 6532 DEXFENFLURAMINE CHEMBL248702 inhibitor TdgClinicalTrial, TEND, DrugBank 14675103, 14515341, 15266556, 11259539, 11325413
SLC6A4 6532 CHEMBL126506 CHEMBL126506 negative modulator DrugBank 17209801, 17139284, 17016423, 10773193
SLC6A4 6532 TAPENTADOL CHEMBL1201776 inhibitor DrugBank 22698264
SLC6A4 6532 LEVOMILNACIPRAN CHEMBL99946 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank
SLC6A4 6532 BUTRIPTYLINE CHEMBL2110816 antagonist, Inhibitor DrugBank 3816971, 9537821, 6086881
SLC6A4 6532 AMITIFADINE CHEMBL592374 TdgClinicalTrial
SLC6A4 6532 CITALOPRAM CHEMBL549 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 DOTHIEPIN (CHEMBL1492500) CHEMBL1492500 inhibitor GuideToPharmacologyInteractions
SLC6A4 6532 DOXEPIN CHEMBL1628227 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 FLUVOXAMINE CHEMBL814 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 PROTRIPTYLINE CHEMBL668 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
SLC6A4 6532 VILAZODONE CHEMBL439849 inhibitor GuideToPharmacologyInteractions, TTD
SLC6A4 6532 TRAMADOL CHEMBL1237044 TdgClinicalTrial, TEND
SLC6A4 6532 CHEMBL1079460 CHEMBL1079460 inhibitor TTD
SLC6A4 6532 PSEUDOEPHEDRINE CHEMBL1590 TdgClinicalTrial
SLC6A4 6532 CHEMBL131495 CHEMBL131495 blocker TTD
SLC6A4 6532 TEDATIOXETINE CHEMBL2104986 TdgClinicalTrial
SLC6A4 6532 LUBAZODONE HYDROCHLORIDE CHEMBL1822892 inhibitor TTD
SLC6A4 6532 TESOFENSINE CHEMBL2107788 TdgClinicalTrial
SLC6A4 6532 CHEMBL528995 CHEMBL528995 TdgClinicalTrial
SLC6A4 6532 TRAZODONE CHEMBL621 TdgClinicalTrial, TEND
SLC6A4 6532 BICIFADINE CHEMBL511099 DrugBank 17325229

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) methylphenidate efficacy no This was based on parental retrospective yes/no reports about response. No association was found between response and the (long)L-A,L-G or (short)S variants. SLC6A4 HTTLPR short form (S allele) is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to SLC6A4 HTTLPR long form (L allele). 17948872 1184168799
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) citalopram efficacy no Response was defined as response (Clinical Global Impressions - Improvement </=2). Association was non-significant following Bonferroni correction. 5-HTTLPR was amplified, and the two amplification products (528bp and 484bp for the long and short alleles respectively) were separated on 2% agarose gel. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram in children with Depressive Disorder as compared to SLC6A4 HTTLPR short form (S allele). 23510446 1184503573
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) venlafaxine efficacy no For 5-HTTLPR genotyping, the homozygotes were designated as L/L (528 bp, 16 copies) or S/S (484 bp, 14 copies), and the heterozygotes designated as L/S. SLC6A4 HTTLPR long form (L allele) is not associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 19468717 1184512708
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) citalopram efficacy no SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 19468717 1451254722
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) fluvoxamine efficacy yes This association was only significant at the 4th and 6th week of treatment and only if both treatments were pooled as antidepressant treament. HTTLPR: Genotyping Deckert 1997 (PMID: 9264139) According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 16874005 1183959953
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) nortriptyline efficacy no At the end of the study (after 12 weeks), there were no differences between ll and s groups in the number of responders (HRSD less than or equal to 10). S and l alleles were determined using DNA amplification (PCR) and established flanking primers according Edenberg et al. PMID:9800223. SLC6A4 HTTLPR short form (S allele) is not associated with response to nortriptyline or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele). 11027924 1183944224
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) sertraline efficacy no Response was measured using HAM-D and CGI- scores. SLC6A4 HTTLPR long form (L allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 18452396 1184483570
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) paroxetine efficacy no Responder analyses were conducted based on changes in CGI-I scores after 10 weeks of treatment. SLC6A4 HTTLPR long form (L allele) is not associated with response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele). 16822601 1184511256
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) escitalopram efficacy yes SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 19567893 1184483616
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) nortriptyline efficacy no SLC6A4 HTTLPR long form (L allele) is not associated with increased response to nortriptyline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 19567893 1184483668
SLC6A4 rs57098334 (CCCACCCGA)12/(CCCACCCGA)12 fluoxetine efficacy yes Patients carrying the 12/12 VNTRs were compared to 9 and 10 VNTRs. Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major. 17018806 1184513240
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) fluvoxamine efficacy no Assessment with Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores. SLC6A4 HTTLPR long form (L allele) is not associated with response to fluvoxamine in people with Obsessive-Compulsive Disorder as compared to SLC6A4 HTTLPR short form (S allele). 12082589 1184511110
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) fluoxetine efficacy yes For statistical power, the samples were enriched with the l/l carriers 5-HTTLPR polymorphism, L/L carriers are rare in Koreans. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele). 22885912 1184509880
SLC6A4 rs57098334 (AGCCCACCC)12 nortriptyline efficacy no Referred to in the paper as STin2. No significant association between this variant, nortriptyline treatment and prolonged smoking abstinence rates (i.e. 52 weeks) or 7-day point prevalence abstinence rates. Allele (AGCCCACCC)12 is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9. 21658141 1450812984
SLC6A4 rs57098334 (CCCACCCGA)12/(CCCACCCGA)12 fluoxetine efficacy yes Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression. 10683861 769171479
SLC6A4 rs57098334 (CCCACCCGA)12/(CCCACCCGA)12 fluvoxamine efficacy no Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with response to fluvoxamine in people with Depression. 12374640 769171488
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) paroxetine efficacy no Subjects with the S/S genotype (n=30) showed a trend of improved clinical response compared with those with the L/S genotype (n=14) (p=0.087); however, no significant difference in clinical response was observed between subjects with the S/S (n=25) and L/S (n=10) genotype at 4 weeks after the initiation of pharmacotherapy (p=0.140). Oligonucleotide primers flanking the 5-HTTLPR and corresponding to the nucleotide positions -1416 to -1397 (5-GGCGTTGCCGCTCTGAATTGC) and from -910 to -889 (5-GAGGGACTGAGCTGGACAACCCAC) of the SLC6A4 gene regulatory region were used to generate a 484(short)/528(long) bp fragment based on ref.8929413, 8632190. Multiple regression analysis revealed that the plasma concentrations of paroxetine, 5-HTTLPR genotype, and -1019C/G HTR1A gene polymorphism were significant factors affecting clinical response to paroxetine (reduction ratio of PAS score) at 2 weeks after the initiation of pharmacotherapy. The -1019C/G HTR1A gene promoter polymorphism, PAS score at baseline, and adverse effects were found to be the significant factors affecting clinical response to PAX at 4 weeks after initiation of pharmacotherapy. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele). 21688171 1183849112
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) escitalopram efficacy yes SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in men with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 19567893 1184483645
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) sertraline efficacy yes Patients were assessed using the Clinician-Administered posttraumatic stress disorder Scale (CAPS). Response was defined as ¿30% improvement in CAPS total score with a CGI-I score of 1 or 2. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with posttraumatic stress disorder as compared to SLC6A4 HTTLPR short form (S allele). 21962566 1184509540
SLC6A4 rs25531 C antipsychotics efficacy yes 6 week response was assessed. Allele C is not associated with response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to allele T. 20031235 981500957
SLC6A4 rs25531 T clozapine efficacy yes An association was found when rs25531 was considered in combination with the "Long" and "Short" alleles of rs4795541. rs25531 subdivides "Long" into La and Lg. Lg + S were grouped together into group S'. Nonresponders to clozapine showed a higher frequency of S'-allele (P = 0.01) and also were more likely to be S'/S' homozygous or S'/La heterozygous than those who did respond (OR = 3.15; 95% CI 1.13-8.80; p = 0.04). Allele T is associated with response to clozapine in people with Schizophrenia. 20452607 981502588
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) sertraline efficacy yes The association was only significant for week 1 and 2 for response based on the CGI-I scale. A trend was found for weeks 4, 6, and 8, but it did not reach statistical significance. No significance was reached when using the HAM-D scale to assess response. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 12955294 1184483446
SLC6A4 SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T HTTLPR short form (S allele)/L allele-rs25531C clozapine efficacy yes An association was found when the "Long" and "Short" alleles were considered in combination with rs25531 (which subdivides "Long" into La and Lg). Lg + S were grouped together into group S'. Nonresponders to clozapine showed a higher frequency of S'-allele (P = 0.01) and also were more likely to be S'/S' homozygous or S'/La heterozygous than those who did respond (OR = 3.15; 95% CI 1.13-8.80; p = 0.04). SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C is associated with decreased response to clozapine in people with Schizophrenia as compared to SLC6A4 L allele-rs25531T. 20452607 1184168791
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) fluoxetine "dosage","efficacy" no There was no placebo group in this trial. The association tested was with response at 4 weeks. The alleles were referred to as "short" and "long" rather than by genotype. The Long group was further subdivided into "La" and "Lg" (reported for rs25531). SLC6A4 HTTLPR short form (S allele) is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele). 20584552 1184168783
SLC6A4 rs25531 C citalopram efficacy no Allele C is not associated with response to citalopram in people with Depression as compared to allele T. 18618621 981477870
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) escitalopram efficacy no SLC6A4 HTTLPR long form (L allele) is not associated with increased response to escitalopram in women with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 19567893 1184483660
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) sertraline efficacy no But the association was not significant. However, a significantly higher frequency of the s allele was observed in responders than in non-responders (chi square = 0.051, p=0.037). SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele). 19825907 1184509867
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR short form (S allele) antipsychotics efficacy yes The L/S (Long/Short) genotype was associated with better negative symptom response to antipsychotic treatment, especially olanzapine, than either of the homozygous genotypes were. This article described the alleles only as L and S- not clear on exact sequence. Association was significant for the SANS but not the BPRS or SAPS. 6 week response was assessed. SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele). 20031235 1184168762
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) fluoxetine efficacy yes Response was assessed using HAM-D scale. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 12476327 1184484028
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) paroxetine efficacy yes (9 patients L/S, 18 S/S) At a paroxetine concentration below 28 ng/ml S/S genotype were more likely to show a percent reduction in PAS score > 20% than those with the L/S genotype. Multiple regression analysis revealed that the plasma concentration of PAX, 5-HTTLPR genotype, and comorbid physical illness were significant factors affecting the initial pharmacotherapeutic effect of PAX in PD and indicated that these factors accounted for 52.4% (R(2) = 0.524) of the variability in the percent reduction in PAS score. Oligonucleotide primers flanking the 5-HTTLPR and corresponding to the nucleotide positions -1416 to -1397 (5-GGCGTTGCCGCTCTGAATTGC) and from -910 to -889 (5-GAGGGACTGAGCTGGACAACCCAC) of the SLC6A4 gene regulatory region were used to generate a 484(short)/528(long) bp fragment based on ref.8929413, 8632190. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele). 19259652 1183849125
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) paroxetine efficacy no SLC6A4 genotype was determined by PCR (Gelernter et al.,1997, PMID:9402979). According to reference . (5-ATG CCA GCA CCT AAC CCC TAA TGT-3) and (5-GG ACC GCA AGG TGG GCG GGA-3), which amplify a 419-bp product from the 16-repeat allele and a 375-bp product from the 14-repeat allele.The distribution of allele frequency in L/L, L/S, and S/S were 6, 30, and 24, respectively. The treatment-response rates were not significantly different between the patients with the L allele (L/L, L/S) and S allele (S/S) either at 4 weeks or 8 weeks SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) are not associated with response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 19606452 1183849138
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) paroxetine efficacy yes Association not find in male participants. Panic Associated Symptoms Scale (PASS) to assess frequency of panic attacks. SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in women with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 16034444 1184508133
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) fluvoxamine efficacy yes Note: Genotyping information are referred to Deckert et al. (PMID:9264139). According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. L/L carrier =2 (both receiving paroxetine), L/S carrier = 22, S/S carrier = 40. The improved response is based on the basis of total (P=0.058), and somatic anxiety (P=0.026) HAM-D score percentage reduction after 4 weeks of medication. SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 15812265 1183849063
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) antidepressants efficacy yes Response assessed with HAM-D score. For the full sample set (male+female): SSRI (paroxetine, fluoxetine, escitalopram, citalopram, sertraline) (n = 37), SNRI (venlafaxine) (n = 27), tricyclics (clomipramine, amitriptyline, dosulepine, imipramine) (n = 30) and other antidepressants (mianserine, mirtazapine, tianeptine, iproniazide) (n = 9) SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to antidepressants in women Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele). 19451862 1184483749
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) fluvoxamine efficacy yes according to ref:9857976 which ref: 9264139 According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine or paroxetine in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele). 15274037 1183944189
SLC6A4 SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) paroxetine efficacy yes as compared to S/S carriers (n=40 for paroxetine or fluvoxamine treatment) with fluvoxamine treatment evaluated by the total (P=0.012), and core (P=0.049) HAM-D score percentage reduction after 4 weeks of medication, and the total (P=0.017) HAM-D score percentage reduction after 6 weeks of medication. Note: Genotyping information are referred to Deckert et al. (PMID:9264139). According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine. 15812265 1183849101
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) escitalopram efficacy yes Response was assessed with HAMD at 8 weeks of treatment. SLC6A4 HTTLPR short form (S allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele). 23095326 1184509891
SLC6A4 SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) fluoxetine efficacy yes PCR: (5'-GGCGTTGCCGCTCTGAATGC), and (5'-GAGGGACTGAGCTGGACAACCAC), corresponding to bases -1416-1397 and -910-889 respectively. 5-HTTLPR gave five alleles differing by 44 bp (14, 16, 18, 20, 22 copies of a repetitive sequence comprising a GC-rich 20-23 bp. The most prevalent allele of the 5-HTTLPR polymorphism for the promoter region in the Korean population was the shortest allele, the 14-copy allele. This allele is designated s and all others are designated l. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major. 10683861 1183944237
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) paroxetine efficacy yes Genotyping following ref. deckert 1997 (PMID:9264139) According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. Note patients were not stratified for baseline scores and baseline depression was different among genotype groups. SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 10653220 1183959898
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) paroxetine efficacy no l/l and l/s (n = 17); s/s (n = 22). No association was found at 2,4,or 6th week of treatment. HTTLPR: Genotyping Deckert 1997 (PMID: 9264139) According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. SLC6A4 HTTLPR long form (L allele) is not associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 16874005 1183959964
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) fluvoxamine efficacy no l/l and l/s (n = 14); s/s (n = 27). No association was found at 2or 6th week of treatment. There was an association with better response for L allele carrier at week 4 (p=0.011). HTTLPR: Genotyping Deckert 1997 (PMID: 9264139) According to this reference, a fragment was amplified and gel separated allowing the differentiation between 528bp of the long form and 484 bp for the short form. SLC6A4 HTTLPR long form (L allele) is not associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 16874005 1183959975
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) citalopram efficacy no Citalopram treatment: mean initial dose: 26.4; range:20-40 mg/day. Genotyped using PCR and length determination via gel. Clinical response to citalopram at 4th week, 89 patients (68%) were classified as Responders (Rp) and 42 (32%) as Non Responders (N-Rp). Genotype distribution for the 5-HTTLPR polymorphism showed no significant differences between both groups ([chi]2 = 0.77, P = 0.68). No significant differences between both subgroups of patients in the distribution of homozygous S/S versus allele L carriers were found either ([chi]2 = 0.03, P = 0.87). SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 14624186 1184472450
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) fluoxetine efficacy yes Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 16302021 1184511344
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) fluvoxamine efficacy yes Genotype was determined via PCR, long (528 bp) and the short (484 bp) variant. The response rate for 5-HTTLPR l/l was 87.5%, whereas it was 75.5% for l/s and 70.4 for s/s. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele). 11543734 1184472345
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) escitalopram efficacy yes 17-item Hamilton Depression scale (HDRS), Clinical Global Impression Scale, and an adverse events scale (UKU) were assessed over 8 weeks. Association was only significant for HDRS scale. For every l allele a participant carried, there was a 3.33 (95% confidence interval 1.25, 8.84; p=0.02) times greater odds of escitalopram response. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 24014145 1184511121
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) venlafaxine efficacy no 17-item Hamilton Depression scale (HDRS), Clinical Global Impression Scale, and an adverse events scale (UKU) were assessed over 8 weeks. Cohort consisted of Asian and Caucasian subjects. SLC6A4 HTTLPR long form (L allele) is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 24014145 1184511132
SLC6A4 rs57098334 (CCCACCCGA)12/(CCCACCCGA)12 fluoxetine efficacy no Responders were defined as patients with at least 50% decrease in HAM-D total score after 4-week fluoxetine treatment. Genotype (CCCACCCGA)12/(CCCACCCGA)12 is not associated with increased response to fluoxetine in people with Depressive Disorder, Major. 16302021 1184511375
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) fluvoxamine efficacy yes Genotype was determined by PCR. Treated with fluvoxamine 300 mg per day combined with a placebo (n = 53). 21-item HDRS was administered was the outcome measure and was administered at baseline and every week thereafter until week 6. Both l/l and l/s subjects had significantly better scores than s/s genotype carriers starting from week 2 to week 6 (P = 0.0283 and P = 0.0012 at week 2, respectively; P , 0.0001 for all other comparisons). SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 9857976 1184472274
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) fluvoxamine efficacy no Genotype was determined by PCR. Treated with fluvoxamine 300 mg per day combined with pindolol 2.5 mg t.i.d. (n = 46). 21-item HDRS was administered was the outcome measure and was administered at baseline and every week thereafter until week 6. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is not associated with response to fluvoxamine and pindolol in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 9857976 1184472326
SLC6A4 SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) fluvoxamine efficacy yes SLC6A4 HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major. 11817517 1184509840
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) citalopram efficacy yes For 5-HTTLPR genotyping, the homozygotes were designated as L/L (528 bp, 16 copies) or S/S (484 bp, 14 copies), and the heterozygotes designated as L/S. SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele). 19468717 1184512692
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele) antidepressants efficacy no Patients treated with selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Response was evaluated using CGI (item 2) (improvement) score 4 weeks after admission to hospital. SLC6A4 HTTLPR short form (S allele) is not associated with response to antidepressants in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele). 16515395 1184513500
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) fluoxetine efficacy yes SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele). 17018806 1184513231
SLC6A4 rs7224199 T morphine dosage no Alleles are reported as given in the paper. Allele T is not associated with dose of morphine in people with Lung Neoplasms and Pain as compared to allele G. 32432768 1451148974
SLC6A4 rs1042173 CC morphine dosage yes Genotype CC is associated with decreased dose of morphine in people with Lung Neoplasms and Pain as compared to genotypes AA + AC. 32432768 1451148962
SLC6A4 rs57098334 (AGCCCACCC)12 sertraline efficacy no Response was measured using HAM-D and CGI- scores. There was no significant difference between the frequency of the 9/10, 10/10, 9/12, 10/12, and 12/12 genotypes and responses to sertraline. Allele (AGCCCACCC)12 is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele (AGCCCACCC)9. 18452396 1184483601
SLC6A4 SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T L allele-rs25531T/L allele-rs25531T fluoxetine efficacy yes Symptom improvement based on the HAM-D17 scale. SLC6A4 L allele-rs25531T/L allele-rs25531T is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531C/L allele-rs25531T. 27439447 1448285601
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR long form (L allele) fluoxetine efficacy yes SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele). 27439447 1448285579
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) sertraline efficacy no No significant difference in HDRS score, CGI score or LUNSERS score between the different genotype groups. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele). 16580768 1449718352
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) sertraline metabolism/PK no SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is not associated with concentrations of sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele). 16580768 1449718371
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR short form (S allele)/HTTLPR short form (S allele) buprenorphine efficacy yes Response defined by changes in the rate of dropout from treatment between genotypes. Authors designate this association as nominally significant as significance was lost following correction for multiple testing. SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele). 29333880 1449271251
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele) nortriptyline efficacy no No significant association between this variant, nortriptyline treatment and prolonged smoking abstinence rates (i.e. 52 weeks) or 7-day point prevalence abstinence rates. SLC6A4 HTTLPR long form (L allele) is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to SLC6A4 HTTLPR short form (S allele). 21658141 1450812962
SLC6A4 rs57098334 (AGCCCACCC)12 bupropion efficacy no Referred to in the paper as STin2. No significant association between this variant, bupropion treatment and prolonged smoking abstinence rates (i.e. 52 weeks) or 7-day point prevalence abstinence rates. Allele (AGCCCACCC)12 is not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotypes (AGCCCACCC)10/(AGCCCACCC)10 + (AGCCCACCC)10/(AGCCCACCC)9. 21658141 1450812991
SLC6A4 rs25531 C bupropion efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant, bupropion treatment and prolonged smoking abstinence rates (i.e. 52 weeks) or 7-day point prevalence abstinence rates. Allele C is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele T. 21658141 1450812977
SLC6A4 SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele) HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele) bupropion efficacy yes There was a significant increase in prolonged smoking abstinence levels (i.e. 52 weeks) and 7-day point prevalence abstinence in subjects carrying at least one copy of the L allele and treated with bupropion while subjects with the S/S genotype did not show any significant effects of bupropion on prolonged abstinence rates. SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele) are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele). 21658141 1450812948
SLC6A4 rs25531 C fluoxetine "dosage","efficacy" no There was no placebo group in this trial. The association tested was with response at 4 weeks. Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T. 20584552 981502205
SLC6A4 rs25531 C venlafaxine efficacy no Response assessed as remission, defined as MADRS score =<10 at the end of treatment. Allele C is not associated with response to venlafaxine in people with Depressive Disorder, Major as compared to allele T. 28068779 1448601808
SLC6A4 rs25531 C nortriptyline efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant, nortriptyline treatment and prolonged smoking abstinence rates (i.e. 52 weeks) or 7-day point prevalence abstinence rates. Allele C is not associated with response to nortriptyline in people with Tobacco Use Disorder as compared to allele T. 21658141 1450812970